Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 950571, 9 pages
http://dx.doi.org/10.1155/2015/950571
Research Article

Sitagliptin: Is It Effective in Routine Clinical Practice?

1Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
2School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor, Malaysia
3Department of Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

Received 26 July 2014; Revised 8 September 2014; Accepted 8 September 2014

Academic Editor: Ilias Migdalis

Copyright © 2015 Rita Mohan Dallumal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, “Diabetes programme: country and regional data,” http://www.who.int/diabetes/facts/world_figures/en/.
  2. International Diabetes Federation, One Adult in Ten will have Diabetes by 2030, http://www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th-edition.
  3. G. R. Letchuman, W. M. Wan Nazaimoon, W. B. Wan Mohamad et al., “Prevalence of diabetes in the Malaysian National Health Morbidity Survey III 2006,” The Medical Journal of Malaysia, vol. 65, no. 3, pp. 173–179, 2010. View at Google Scholar · View at Scopus
  4. W. M. Wan Nazaimoon, S. H. Md Isa, W. B. Wan Mohamad et al., “Prevalence of diabetes in Malaysia and usefulness of HbA1c as a diagnostic criterion,” Diabetic Medicine, vol. 30, no. 7, pp. 825–828, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. Clinical Practice Guidelines: Management of Type 2 Diabetes Mellitus, MOH/P/PAK/184.09(GU), Malaysian Endocrine and Metabolic Society, Ministry of Health Malaysia, Academy of Medicine Malaysia, Persatuan Diabetes Malaysia, Kuala Lumpur, Malaysia, 4th edition, 2009.
  6. American Diabetes Association (ADA), “Standards of medical care in diabetes—2014,” Diabetes Care, vol. 37, pp. S14–S80, 2014. View at Google Scholar
  7. S. S. Chua and S. P. Chan, “Medication adherence and achievement of glycaemic targets in ambulatory type 2 diabetic patients,” Journal of Applied Pharmaceutical Science, vol. 1, no. 4, pp. 55–59, 2011. View at Google Scholar · View at Scopus
  8. S. VanDeKoppel, H. M. Choe, and B. V. Sweet, “Managed care perspective on three new agents for type 2 diabetes,” Journal of Managed Care Pharmacy, vol. 14, no. 4, pp. 363–380, 2008. View at Google Scholar · View at Scopus
  9. D. T. Eurich, S. Simpson, A. Senthilselvan, C. V. Asche, J. K. Sandhu-Minhas, and F. A. McAlister, “Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study,” The British Medical Journal, vol. 346, no. 7908, Article ID f2267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. G. A. Herman, A. Bergman, C. Stevens et al., “Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4612–4619, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. A. J. Bergman, C. Stevens, Y. Zhou et al., “Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers,” Clinical Therapeutics, vol. 28, no. 1, pp. 55–72, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Nonaka, T. Kakikawa, A. Sato et al., “Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 79, no. 2, pp. 291–298, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Aschner, M. S. Kipnes, J. K. Lunceford, M. Sanchez, C. Mickel, and D. E. Williams-Herman, “Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes,” Diabetes Care, vol. 29, no. 12, pp. 2632–2637, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M.-N. Chien, C.-C. Lee, W.-C. Chen, S.-C. Liu, C.-H. Leung, and C.-H. Wang, “Effect of sitagliptin as add-on therapy in elderly type 2 diabetes patients with inadequate glycemic control in Taiwan,” International Journal of Gerontology, vol. 5, no. 2, pp. 103–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. B. J. Goldstein, M. N. Feinglos, J. K. Lunceford, J. Johnson, and D. E. Williams-Herman, “Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes,” Diabetes Care, vol. 30, no. 8, pp. 1979–1987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. National Institute for Health and Clinical Excellence, NICE Clinical Guideline: Type 2 Diabetes, National Institute for Health and Clinical Excellence, London, UK, 2009.
  17. T. L. Seck, S. S. Engel, D. E. Williams-Herman et al., “Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide,” Diabetes Research and Clinical Practice, vol. 93, no. 1, pp. e15–e17, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Raz, M. Hanefeld, L. Xu, C. Caria, D. Williams-Herman, and H. Khatami, “Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.,” Diabetologia, vol. 49, no. 11, pp. 2564–2571, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. G. A. Herman, G. C. Mistry, B. Yi et al., “Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males,” British Journal of Clinical Pharmacology, vol. 71, no. 3, pp. 429–436, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. Clinical Practice Guidelines on Management of Obesity, Ministry of Health Malaysia, Academy of Medicine Malaysia, Malaysian Association for the Study of Obesity, Malaysian Endocrine and Metabolic Society, Kuala Lumpur, Malysia, 2004.
  21. R. J. Little and D. B. Rubin, Statistical Analysis with Missing Data, John Wiley & Sons, New York, NY, USA, 1987.
  22. B. Ahrén, “DPP-4 inhibitors,” Best Practice and Research in Clinical Endocrinology and Metabolism, vol. 21, no. 4, pp. 517–533, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C. L. Boland, M. DeGeeter, D. S. Nuzum, and M. Tzefos, “Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors,” Annals of Pharmacotherapy, vol. 47, no. 4, pp. 490–505, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. A. Nauck, G. Meininger, D. Sheng et al., “Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial,” Diabetes, Obesity and Metabolism, vol. 9, no. 2, pp. 194–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Rosenstock, R. Brazg, P. J. Andryuk, K. Lu, and P. Stein, “Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study,” Clinical Therapeutics, vol. 28, no. 10, pp. 1556–1568, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Karagiannis, P. Paschos, K. Paletas, D. R. Matthews, and A. Tsapas, “Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis,” British Medical Journal, vol. 344, no. 7850, Article ID e1369, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Giampietro, C. Giampietro, L. D. Bartola, M. C. Masoni, and E. Matteucci, “Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes,” Drug Design, Development and Therapy, vol. 7, pp. 99–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Kanamori and I. Matsuba, “Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer,” Journal of Clinical Medicine Research, vol. 5, no. 3, pp. 217–221, 2013. View at Google Scholar
  29. T. Y. Chen and C. J. Hsieh, “Real-world effectiveness of sitagliptin as add-on therapy in patients with Type 2 diabetes mellitus,” Postgraduate Medicine, vol. 126, no. 3, pp. 205–215, 2014. View at Publisher · View at Google Scholar
  30. M. Mafauzy, “Diabetes control and complications in public hospitals in Malaysia,” Medical Journal of Malaysia, vol. 61, no. 4, pp. 477–483, 2006. View at Google Scholar · View at Scopus
  31. T. Nomiyama, Y. Akehi, H. Takenoshita et al., “Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 95, no. 2, pp. e27–e28, 2012. View at Publisher · View at Google Scholar · View at Scopus